Baduanjin exercise alleviates anxiety, depressive symptoms, and improves sleep quality and quality of life in patients with primary glaucoma
An 8-week Baduanjin exercise intervention (5 sessions per week, 30 min each) significantly improved anxiety (HADS-A), depressive symptoms (HADS-D), and sleep quality (PSQI) compared to routine care in patients with primary glaucoma. Benefits were more pronounced in patients with higher baseline symptom levels. The intervention also improved domain-specific quality of life, particularly glare/dark adaptation and outdoor mobility.
Evidence Score
Study Evidence
Study 1. Effects of Baduanjin on anxiety, depressive symptoms, and quality of life in patients with primary glaucoma: A randomized controlled trial.
observationalZeng Z, Li X, Ma X, Guo J, Qin L ยท Complementary therapies in clinical practice (2026)
Result:
Mechanism Graph
Limitations
- โ Single-center study may limit generalizability
- โ No blinding of participants or instructors due to the nature of the exercise intervention
- โ Short follow-up period (8 weeks) without long-term outcome assessment
Frequently Asked Questions
What is Baduanjin?โผ
Baduanjin is a traditional Chinese mind-body exercise involving slow, coordinated movements and breathing, often described as 'Eight Brocades'.
How long did the Baduanjin intervention last?โผ
The intervention lasted 8 weeks, with five 30-minute sessions per week.
What outcomes improved in the Baduanjin group?โผ
Anxiety, depressive symptoms, sleep quality, and quality of life (specifically glare/dark adaptation and outdoor mobility) improved significantly compared to the control group.
Was the effect of Baduanjin the same for all patients?โผ
No, the benefits were more pronounced in patients with higher baseline levels of anxiety, depression, or sleep problems.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Zeng Z, Li X, Ma X, Guo J, Qin L. "Effects of Baduanjin on anxiety, depressive symptoms, and quality of life in patients with primary glaucoma: A randomized controlled trial.." Complementary therapies in clinical practice, 2026. PMID: 42431068 DOI: 10.1016/j.ctcp.2026.102077